LAVA Therapeutics NV LVTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
3.05quote price arrow down-0.04 (-1.29%)
Volume
489
Close
3.09quote price arrow down-0.02 (-0.64%)
Volume
31,194
52 week range
1.13 - 6.47
Loading...
  • Open3.15
  • Day High3.17
  • Day Low3.04
  • Prev Close3.11
  • 52 Week High6.47
  • 52 Week High Date02/29/24
  • 52 Week Low1.13
  • 52 Week Low Date10/30/23

Key Stats

  • Market Cap81.233M
  • Shares Out26.29M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta0.8
  • YTD % Change95.57

KEY STATS

  • Open3.15
  • Day High3.17
  • Day Low3.04
  • Prev Close3.11
  • 52 Week High6.47
  • 52 Week High Date02/29/24
  • 52 Week Low1.13
  • 52 Week Low Date10/30/23
  • Market Cap81.233M
  • Shares Out26.29M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta0.8
  • YTD % Change95.57

RATIOS/PROFITABILITY

  • EPS (TTM)-1.58
  • P/E (TTM)-1.95
  • Fwd P/E (NTM)-2.03
  • EBITDA (TTM)-41.975M
  • ROE (TTM)-61.18%
  • Revenue (TTM)6.769M
  • Gross Margin (TTM)48.56%
  • Net Margin (TTM)-620.09%
  • Debt To Equity (MRQ)12.34%

EVENTS

  • Earnings Date06/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On LAVA Therapeutics NV

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Kapil Dhingra
Non-Executive Chairman of the Board
Stephen Hurly
President, Chief Executive Officer, Management Director
Edward Smith
Chief Financial Officer
Paul Parren
Executive Vice President Head of Research and Development
Amy Garabedian
General Counsel, Corporate Secretary
Address
Yalelaan 60
Utrecht
3584 CM
Netherlands

Top Peers

SYMBOLLASTCHG%CHG
KZR
Kezar Life Sciences Inc
0.7727-0.0443-5.4223%
AFMD
Affimed NV
5.25+0.01+0.29%
ARMP
Armata Pharmaceuticals Inc
3.01-0.25-7.67%
KRON
Kronos Bio Inc
1.02-0.03-2.86%
CUE
Cue Biopharma Inc
1.74-0.18-9.14%